Revolution Medicines (NASDAQ:RVMDW – Get Free Report) will likely be releasing its results before the market opens on Wednesday, February 25th. Analysts expect Revolution Medicines to post earnings of ($1.5782) per share and revenue of $3.8940 million for the quarter.
Revolution Medicines Trading Up 5.0%
Shares of NASDAQ RVMDW opened at $1.89 on Tuesday. The firm’s 50 day moving average price is $1.73 and its 200-day moving average price is $0.87. Revolution Medicines has a 52-week low of $0.03 and a 52-week high of $3.59.
About Revolution Medicines
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
Recommended Stories
- Five stocks we like better than Revolution Medicines
- Elon Musk already made me a “wealthy man”
- Elon’s Secret AI Partner?
- Silver $500? The “Deficit Math” says it’s possible.
- Elon Musk: This Could Turn $100 into $100,000
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
